To accelerate the drug discovery process using Artificial Intelligence (AI), Servier and Oncodesign Precision Medicine (OPM) are launching FederAidd, an international virtual campus for open innovation on December 15.

The goal of FederAidd (Federation for Artificial Intelligence in Drug Discovery) is to bring together key players and promote exchanges revolving around AI projects applied to the discovery of innovative drugs that meet unmet medical needs. A joint initiative between members based in Dijon and Paris-Saclay, France, and Montreal, Canada, it will host healthcare stakeholders from all over the world.

The platform offers members a space for experimentation, training, and reflection within the scope of drug discovery or entrepreneurship projects.

FederAidd also makes a collective intelligence corpus available, which is based on a collaborative platform that pools the tools and knowledge shared on the virtual campus.

“We are very pleased to launch FederAidd with our long-time partner OPM. This virtual open innovation campus aims to bring together different players in the healthcare ecosystem from all over the world, such as academic groups, biotechs, star-tup or pharmaceutical groups, in order to stimulate the discovery of new treatments, and to accelerate therapeutic innovation through artificial intelligence.”

Olivier Nosjean, Director of Open Innovation and Scientific Affairs at Servier